GT BIOPHARMA INC (GTBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.24-4.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GTBP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GTBP — capital allocation — Material Modifications to Rights of Security Holders
Dated 2026-09-03
Material Modifications to Rights of Security Holders. To the extent required by
Why it matters: Updates on this notice will show if the company is on track to regain compliance. It affects investor trust.
Worry ifGT Biopharma gives a good update on its work to follow Nasdaq rules.
Less concerning ifNo progress is seen on compliance work, which may lead to delisting.
Why it matters: Regaining compliance is crucial for GT Biopharma's stock listing. Failure could lead to delisting.
Worry ifThe company meets Nasdaq listing rules by the November deadline.
Less concerning ifThe company fails to regain compliance by the November deadline.
Why it matters: Starting the trial is a key step for GTB-5550's development. It could impact future funding.
Supportive ifThe company officially announces the start of the phase 1a/1b clinical trial for GTB-5550.
Worry ifThe company delays or cancels the start of the clinical trial.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$462 on $10,000 · ±4.6% | How much price usually moves either way. |
| Bad day | $1,103 loss on $10,000 · 11.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,769 loss on $10,000 · 77.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.